Should I buy or sell Dermira stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dermira in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DERM shares. View DERM analyst ratings or view top-rated stocks .

What is Dermira's stock price target for 2024?

1 equities research analysts have issued 1-year target prices for Dermira's shares. Their DERM share price targets range from $6.00 to $6.00. On average, they expect the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 3.1% from the stock's current price. View analysts price targets for DERM or view top-rated stocks among Wall Street analysts .

Are investors shorting Dermira?

Dermira saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 44,600 shares, a decrease of 45.2% from the October 31st total of 81,400 shares. Based on an average trading volume of 99,300 shares, the short-interest ratio is currently 0.4 days. Approximately 0.7% of the shares of the stock are sold short. View Dermira's Short Interest .

When is Dermira's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024. View our DERM earnings forecast .

How were Dermira's earnings last quarter?

Dermira Inc (NASDAQ:DERM) released its quarterly earnings results on Tuesday, November, 7th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.96. The biopharmaceutical company earned $34.54 million during the quarter, compared to analyst estimates of $16.88 million. Dermira had a negative net margin of 15.46% and a negative trailing twelve-month return on equity of 118.05%.

What other stocks do shareholders of Dermira own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dermira investors own include Advanced Micro Devices (AMD) , Gilead Sciences (GILD) , Novavax (NVAX) , Micron Technology (MU) , Inovio Pharmaceuticals (INO) , Karyopharm Therapeutics (KPTI) , Pfizer (PFE) , AT&T (T) , Exelixis (EXEL) and ImmunoGen (IMGN) .

When did Dermira IPO?

(DERM) raised $39 million in an initial public offering on Friday, November 12th 2021. The company issued 3,520,000 shares at a price of $10.00-$12.00 per share.

Dermira Stock Price, News & Analysis (NASDAQ:DERM)

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $5.54
▼
$6.87
50-Day Range: $18.73
▼
$18.85
52-Week Range: $5.25
▼
$19.48

Volume: 536,644 shs
Average Volume: 185,571 shs
Market Capitalization: $107.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

Stock Analysis Analyst Forecasts Competitors Earnings Headlines Insider Trades Short Interest Social Media

Dermira MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 3.1% Upside
$6.00 Price Target
Short Interest: Healthy
0.74% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 5 Articles This Week
Insider Trading: Acquiring Shares
$232,140 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.16) to ($0.35) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.46 out of 5 stars

Medical Sector

881st out of 954 stocks

Pharmaceutical Preparations Industry

336th out of 362 stocks

1.5

Analyst's Opinion

Consensus Rating
Dermira has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.00, Dermira has a forecasted upside of 3.1% from its current price of $5.82.
Amount of Analyst Coverage
Dermira has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.74% of the float of Dermira has been sold short.
Short Interest Ratio / Days to Cover
Dermira has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Dermira has recently decreased by 45.21%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Dermira does not currently pay a dividend.
Dividend Growth
Dermira does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DERM.

1.1

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 5 news articles for Dermira this week, compared to 0 articles on an average week.
Search Interest
14 people have searched for DERM on MarketBeat in the last 30 days. This is an increase of 1,300% compared to the previous 30 days.
MarketBeat Follows
9 people have added Dermira to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Dermira insiders have bought 1,271.82% more of their company's stock than they have sold. Specifically, they have bought $232,140.00 in company stock and sold $16,922.00 in company stock.
Percentage Held by Insiders
19.42% of the stock of Dermira is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 8.95% of the stock of Dermira is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Dermira are expected to decrease in the coming year, from ($0.16) to ($0.35) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Dermira is -7.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Dermira is -7.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Dermira has a P/B Ratio of 6.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Dermira Stock (NASDAQ:DERM)

Dermira, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older. It also develops lebrikizumab, a novel injectable humanized monoclonal antibody targeting interleukin 13 that is in Phase IIb clinical trial for the treatment of moderate-to-severe atopic dermatitis; and early-stage research and development programs in other areas of dermatology. Dermira, Inc. has a right of first negotiation agreement with Maruho Co., Ltd. to develop and commercialize glycopyrronium tosylate for the treatment of hyperhidrosis in Japan; an agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize lebrikizumab; and a development and commercialization agreement with UCB Pharma S.A. to develop Cimzia for the treatment of psoriasis. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.

December 7, 2023 | finance.yahoo.com

4 Growth Stocks to Buy Ahead of a Strong Year-End Rally

December 7, 2023 | finance.yahoo.com

Journey Medical (DERM) Up on Update for Skin Disease Candidate

December 8, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

December 7, 2023 | finance.yahoo.com

Journey Medical Corporation's (NASDAQ:DERM) largest shareholders are public companies who were rewarded as market cap surged US$34m last week

December 6, 2023 | finance.yahoo.com

Empress Therapeutics Appoints Virginia Finnerty-Brooks Chief Business Officer

November 30, 2023 | finance.yahoo.com

Are You Looking for a Top Momentum Pick? Why Journey Medical Corporation (DERM) is a Great Choice

November 29, 2023 | finance.yahoo.com

What Makes Journey Medical Corporation (DERM) a Good Fit for 'Trend Investing'

November 12, 2023 | finance.yahoo.com

Journey Medical Corporation (NASDAQ:DERM) Q3 2023 Earnings Call Transcript

December 8, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

October 31, 2023 | finance.yahoo.com

Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023

October 12, 2023 | finance.yahoo.com

Atopic Dermatitis Market 2023 – Uncovering Global Dynamics, Geographical Segmentation, and Forecast 2023-2030

September 25, 2023 | benzinga.com

Hyperhidrosis Treatment Market to Surpass USD 1.71 billion by 2027, Garnering 4.0% CAGR Says, Transparency Market Research

September 11, 2023 | finance.yahoo.com

Journey Medical Gains 40%, Insider Trades Reap Benefit

September 9, 2023 | finance.yahoo.com

Insider Buying: Journey Medical Corp's President & CEO Claude Maraoui Acquires 26,044 Shares

September 7, 2023 | finance.yahoo.com

Journey Medical (DERM) & Maruho Ink Deal for Qbrexza Asia Rights

August 23, 2023 | msn.com

If You Invested $1000 in Eli Lilly a Decade Ago, This is How Much It'd Be Worth Now

August 17, 2023 | finance.yahoo.com

Regulatory Affairs Outsourcing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028

August 8, 2023 | finance.yahoo.com

Journey Medical Corporation (DERM) Reports Q2 Loss, Tops Revenue Estimates

August 8, 2023 | bizjournals.com

Nektar Therapeutics sues Lilly for breach of contract around skin drug

August 2, 2023 | finance.yahoo.com

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023

July 19, 2023 | finance.yahoo.com

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023

July 18, 2023 | fool.com

Arvinas (NASDAQ: ARVN)

July 10, 2023 | finance.yahoo.com

ReCode Therapeutics Appoints Erica Jefferson as Senior Vice President of Corporate Affairs

July 4, 2023 | finance.yahoo.com

Journey Medical (DERM) to Post Skin Disease Data, Stock Rises 26%

June 22, 2023 | marketwatch.com

Hyperhidrosis Treatment market overview showcases immense growth potential and worth with a proper CAGR of 9.7% forcasted from 2023 to 2030

June 14, 2023 | finance.yahoo.com

Journey Medical (DERM) Up on Rosacea Candidate's Positive Data

June 13, 2023 | finance.yahoo.com

Why Are Journey Medical Shares Trading Higher Today

See More Headlines

Receive DERM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dermira and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 12/08/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 4/03/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:DERM
CUSIP: N/A
CIK: 1557883
Web: www.dermira.com
Phone: 650-421-7200
Fax: N/A
Employees: 333
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.00
High Stock Price Target: $6.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +3.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.83)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-29,630,000.00
Net Margins: -15.46%
Pretax Margin: -15.33%
Return on Equity: -118.05%
Return on Assets: -14.68%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.92
Quick Ratio: 0.69

Sales & Book Value

Annual Sales: $73.67 million
Price / Sales: 1.46
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.96 per share
Price / Book: 6.06

Miscellaneous

Outstanding Shares: 18,510,000
Free Float: 14,914,000
Market Cap: $107.73 million
Optionable: Not Optionable
Beta: 0.82

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Thomas G. Wiggans (Age 67)
Co-Founder, CEO & Chairman
Dr. Eugene Andrew Bauer (Age 77)
Co-Founder, Chief Medical Officer & Director
Mr. Andrew L. Guggenhime (Age 51)
Chief Financial Officer
Ms. Lori Lyons-Williams (Age 42)
Chief Commercial Officer
Mr. Christopher M. Griffith (Age 43)
Co-Founder and Chief Bus. & Strategy Officer

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

DERM Stock Analysis - Frequently Asked Questions

Should I buy or sell Dermira stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dermira in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DERM shares.
View DERM analyst ratings or view top-rated stocks.
What is Dermira's stock price target for 2024?: 1 equities research analysts have issued 1-year target prices for Dermira's shares. Their DERM share price targets range from $6.00 to $6.00. On average, they expect the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 3.1% from the stock's current price.
View analysts price targets for DERM or view top-rated stocks among Wall Street analysts.
Are investors shorting Dermira?: Dermira saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 44,600 shares, a decrease of 45.2% from the October 31st total of 81,400 shares. Based on an average trading volume of 99,300 shares, the short-interest ratio is currently 0.4 days. Approximately 0.7% of the shares of the stock are sold short.
View Dermira's Short Interest.
When is Dermira's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our DERM earnings forecast.

How were Dermira's earnings last quarter?: Dermira Inc (NASDAQ:DERM) released its quarterly earnings results on Tuesday, November, 7th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.96. The biopharmaceutical company earned $34.54 million during the quarter, compared to analyst estimates of $16.88 million. Dermira had a negative net margin of 15.46% and a negative trailing twelve-month return on equity of 118.05%.
What other stocks do shareholders of Dermira own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Dermira investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Novavax (NVAX), Micron Technology (MU), Inovio Pharmaceuticals (INO), Karyopharm Therapeutics (KPTI), Pfizer (PFE), AT&T (T), Exelixis (EXEL) and ImmunoGen (IMGN).
When did Dermira IPO?: (DERM) raised $39 million in an initial public offering on Friday, November 12th 2021. The company issued 3,520,000 shares at a price of $10.00-$12.00 per share.

This page (NASDAQ:DERM) was last updated on 12/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Dermira Stock Price, News & Analysis (NASDAQ:DERM)

Dermira MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Dermira Stock (NASDAQ:DERM)

DERM Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

DERM Stock Analysis - Frequently Asked Questions

Overall MarketRank^™